Update news for v4.18 (#1131)

oncokb · Jul 1, 2024 · fcdaa5e · fcdaa5e
1 parent 8c31d28
commit fcdaa5e
Show file tree

Hide file tree

Showing 11 changed files with 214 additions and 7 deletions.
diff --git a/...__baseline_snapshots__/Precision Oncology Therapies Page without Login-snap.png b/...__baseline_snapshots__/Precision Oncology Therapies Page without Login-snap.png
diff --git a/src/main/webapp/app/config/constants.tsx b/src/main/webapp/app/config/constants.tsx
@@ -800,6 +800,7 @@ export type DataRelease = {
 };
 
 export const DATA_RELEASES: DataRelease[] = [
+  { date: '07022024', version: 'v4.18' },
   { date: '06042024', version: 'v4.17' },
   { date: '05012024', version: 'v4.16' },
   { date: '03212024', version: 'v4.15' },

diff --git a/src/main/webapp/app/pages/aboutGroup/FdaRecognitionPage.tsx b/src/main/webapp/app/pages/aboutGroup/FdaRecognitionPage.tsx
@@ -72,7 +72,7 @@ const FdaRecognitionPage = () => {
             <h5>Important Database Links</h5>
             <ul>
               <li>
-                <SopPageLink version={2.0} />
+                <SopPageLink version={4.1} />
               </li>
               <li>
                 <LevelOfEvidencePageLink
@@ -148,7 +148,7 @@ const FdaRecognitionPage = () => {
             <h5>Scope of {ONCOKB_TM} Recognition</h5>
             <p>
               The FDA has reviewed all {ONCOKB_TM} processes documented in the{' '}
-              <SopPageLink version={2.0} />, which include the following:
+              <SopPageLink version={4.1} />, which include the following:
             </p>
             <ol>
               <li>

diff --git a/src/main/webapp/app/pages/newsPage/ChangedAnnotatonListItem.tsx b/src/main/webapp/app/pages/newsPage/ChangedAnnotatonListItem.tsx
@@ -10,6 +10,7 @@ import {
   CHANGED_ANNOTATION_SENSITIVITY_LEVEL_COLUMNS,
   UPDATED_IMPLICATION_COLUMNS,
   CHANGED_ANNOTATION_DRUG_REMOVAL_SAME_HIGHEST_LEVEL_COLUMNS,
+  CHANGED_ANNOTATION_DRUG_SAME_HIGHEST_LEVEL_COLUMNS,
 } from 'app/pages/newsPage/NewsPageContent';
 import { SimpleTable, SimpleTableRow } from 'app/components/SimpleTable';
 import { Row } from 'react-bootstrap';
@@ -32,6 +33,7 @@ export enum AnnotationColumnHeaderType {
   ADDITIONAL_SENSITIVITY_LEVEL_DRUG,
   DRUG_REMOVAL,
   DRUG_REMOVAL_SAME_HIGHEST_LEVEL,
+  DRUG_UPDATE_SAME_HIGHEST_LEVEL,
   DEMOTION_TUMOR_TYPE_SPECIFIC_EVIDENCE,
   PROMOTION_TUMOR_TYPE_SPECIFIC_EVIDENCE,
   NEW_ALTERATION_WITH_LEVEL,
@@ -61,6 +63,11 @@ export const ChangedAnnotationListItem = (props: {
       defaultTitle =
         'Updated therapeutic implications - Addition of therapies for variants with a level of evidence';
       break;
+    case AnnotationColumnHeaderType.DRUG_UPDATE_SAME_HIGHEST_LEVEL:
+      annotationColumnHeader = CHANGED_ANNOTATION_DRUG_SAME_HIGHEST_LEVEL_COLUMNS;
+      useOneLineRowClass = false;
+      defaultTitle = `Updated therapeutic implications - Changed drug specific tumor-type level of evidence for an alteration-tumor type-drug association currently in OncoKB (without changing the alteration's highest level of evidence)`;
+      break;
     case AnnotationColumnHeaderType.ADDITIONAL_DIFF_LEVEL_DRUG:
       annotationColumnHeader = CHANGED_ANNOTATION_ADDITIONAL_DRUG_DIFF_LEVEL_COLUMNS;
       useOneLineRowClass = false;

diff --git a/src/main/webapp/app/pages/newsPage/NewsPage.tsx b/src/main/webapp/app/pages/newsPage/NewsPage.tsx
@@ -91,6 +91,7 @@ export default class NewsPage extends React.Component<{
             <CitationText />
           </div>
           <div className="mt-2">
+            <NewsList date={'07022024'} />
             <NewsList date={'06042024'} />
             <NewsList date={'05012024'} />
             <NewsList date={'03212024'} />

diff --git a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
@@ -83,6 +83,7 @@ export const DRUGS_CURRENTLY_IN_ONCOKB = `Drug(s) currently in ${ONCOKB_TM}`;
 export const DRUGS_REMOVED_FROM_ONCOKB = `Drug(s) removed from ${ONCOKB_TM}`;
 export const DRUGS_DEMOTED_IN_ONCOKB = `Drug(s) demoted in ${ONCOKB_TM}`;
 export const DRUGS_PROMOTED_IN_ONCOKB = `Drug(s) promoted in ${ONCOKB_TM}`;
+export const DRUGS_CHANGED_IN_ONCOKB = `Drug(s) changed in ${ONCOKB_TM}`;
 export const DRUGS_ASSOCIATED_WITH_CURRENT_LEVEL =
   'Drug(s) Associated with the Current Level';
 export const UPDATED_SENSITIVITY_LEVEL = 'Updated Sensitivity Level';
@@ -141,6 +142,16 @@ export const CHANGED_ANNOTATION_DRUG_COLUMNS = [
   { name: EVIDENCE },
 ];
 
+export const CHANGED_ANNOTATION_DRUG_SAME_HIGHEST_LEVEL_COLUMNS = [
+  { name: LEVEL },
+  { name: GENE },
+  { name: MUTATION },
+  { name: CANCER_TYPE },
+  { name: DRUGS_CURRENTLY_IN_ONCOKB },
+  { name: DRUGS_CHANGED_IN_ONCOKB },
+  { name: EVIDENCE },
+];
+
 export const CHANGED_ANNOTATION_ADDITIONAL_DRUG_SAME_LEVEL_COLUMNS = [
   { name: GENE },
   { name: MUTATION },
@@ -250,6 +261,167 @@ const EVIDENCE_COLUMN_SEPARATOR = '; ';
 // https://stackoverflow.com/questions/41947168/is-it-possible-to-use-keyof-operator-on-literals-instead-of-interfaces
 
 export const NEWS_BY_DATE: { [date: string]: NewsData } = {
+  '07022024': {
+    priorityNews: [
+      <span>
+        Release of{' '}
+        <a
+          href="https://sop.oncokb.org/?version=v4.1"
+          target="_blank"
+          rel="noopener noreferrer"
+        >
+          {ONCOKB_TM} SOP v4.1
+        </a>
+      </span>,
+      <span>
+        Updated HUGO symbol for gene SLC9A3R1 to{' '}
+        <GenePageLink hugoSymbol="NHERF1" />
+      </span>,
+    ],
+    changedAnnotations: [
+      {
+        columnHeaderType:
+          AnnotationColumnHeaderType.PROMOTION_TUMOR_TYPE_SPECIFIC_EVIDENCE,
+        content: [
+          [
+            'KRAS',
+            'G12C',
+            'Colorectal Cancer',
+            <div>
+              <div style={{ fontStyle: 'italic' }}>
+                {DRUGS_CURRENTLY_IN_ONCOKB}:
+              </div>
+              <div style={{ textDecoration: 'underline' }}>Sensitivity</div>
+              <div>
+                Adagrasib + Cetuximab, Adagrasib + Panitumumab, Sotorasib +
+                Cetuximab, Sotorasib + Panitumumab (Level 2)
+              </div>
+              <br></br>
+              <div style={{ textDecoration: 'underline' }}>Resistance</div>
+              <div>
+                Tucatinib + Trastuzumab, Cetuximab, Panitumumab (Level R1)
+              </div>
+              <br></br>
+              <div style={{ fontStyle: 'italic' }}>
+                {DRUGS_PROMOTED_IN_ONCOKB}:
+              </div>
+              <div>Adagrasib + Cetuximab (Level 1)</div>
+            </div>,
+            '2',
+            '1',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <FdaApprovalLink
+                approval="Adagrasib + Cetuximab"
+                link="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer"
+              />
+              <PMIDLink pmids="38587856" />
+            </WithSeparator>,
+          ],
+          [
+            'KRAS',
+            'G12C',
+            'Biliary Tract Cancer',
+            'Adagrasib',
+            '3A',
+            '2',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <span>
+                Inclusion in NCCN Biliary Tract Cancer Guidelines V2.2024
+              </span>
+              <PMIDLink pmids="37099736" />
+            </WithSeparator>,
+          ],
+        ],
+      },
+      {
+        columnHeaderType: AnnotationColumnHeaderType.ADDITIONAL_SAME_LEVEL_DRUG,
+        title: `Updated therapeutic implications - Addition of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)`,
+        content: [
+          [
+            'EGFR',
+            'Exon 19 in-frame deletion, L858R',
+            'Non-Small Cell Lung Cancer',
+            '1',
+            'Erlotinib, Afatinib, Gefitinib, Dacomitinib, Erlotinib + Ramucirumab, Osimertinib (Level 1); Patritumab Deruxtecan (Level 3A)',
+            'Osimertinib + Chemotherapy (Level 1); Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib (Level 3A)',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <FdaApprovalLink
+                approval="Osimertinib with Chemotherapy"
+                link="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer"
+              />
+              <span>
+                Inclusion of Amivantamab + Chemotherapy in NCCN Non-Small Cell
+                Lung Cancer Guidelines V5.2024
+              </span>
+              <PMIDLink
+                pmids="37937763, 37710001, 37879444, 38924756"
+                wrapText
+              />
+            </WithSeparator>,
+          ],
+          [
+            'EGFR',
+            'S768I, L861Q, G719X',
+            'Non-Small Cell Lung Cancer',
+            '1',
+            'Afatinib (Level 1); Osimertinib (Level 2); Patritumab Deruxtecan (Level 3A)',
+            'Erlotinib, Gefitinib, Dacomitinib, Amivantamab + Chemotherapy  (Level 2); Amivantamab + Lazertinib (Level 3A)',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <span>
+                Inclusion of Erlotinib, Gefitinib, Dacomitinib and Amivantamab +
+                Chemotherapy in NCCN Non-Small Cell Lung Cancer Guidelines
+                V5.2024
+              </span>
+              <PMIDLink pmids="37879444, 25668120, 35770100" wrapText />
+              <AbstractLink
+                abstract="Cho, B.C. et al., Abstract #8516, ASCO 2024"
+                link="https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516"
+              />
+            </WithSeparator>,
+          ],
+          [
+            'ERBB2',
+            'Amplification',
+            'Biliary Tract Cancer',
+            '2',
+            'Trastuzumab + Pertuzumab',
+            'Tucatinib + Trastuzumab (Level 2)',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <span>
+                Inclusion in NCCN Biliary Tract Cancer Guidelines V2.2024
+              </span>
+              <PMIDLink pmids="37751561" />
+            </WithSeparator>,
+          ],
+        ],
+      },
+      {
+        columnHeaderType:
+          AnnotationColumnHeaderType.DRUG_UPDATE_SAME_HIGHEST_LEVEL,
+        content: [
+          [
+            '1',
+            'NTRK1, NTRK2, NTRK3',
+            'Fusions',
+            'All Solid Tumors',
+            'Larotrectinib, Entrectinib (Level 1); Repotrectinib (Level 3A)',
+            'Repotrectinib (Level 1)',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <FdaApprovalLink
+                approval="Repotrectinib"
+                link="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive"
+              />{' '}
+              <AbstractLink
+                abstract="Solomon, B.J., et al., Abstract #1372P, Ann Oncol Vol 34, Suppl 2, 2023"
+                link="https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext"
+              />
+            </WithSeparator>,
+          ],
+        ],
+      },
+    ],
+    newlyAddedGenes: ['LMNA', 'PRCC', 'UBA1', 'UBTF', 'RIOK2'],
+  },
   '06042024': {
     priorityNews: [
       <span>
@@ -283,7 +455,10 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = {
                 Inclusion in Colon Cancer NCCN Guidelines V2.2024 and in Small
                 Bowel Adenocarcinoma NCCN Guidelines V3.2024
               </span>
-              <PMIDLink pmids="26028255, 31682550, 28734759, 37917058" />
+              <PMIDLink
+                pmids="26028255, 31682550, 28734759, 37917058"
+                wrapText
+              />
               <AbstractLink
                 abstract="Chae et al. Abstract# 3417, AACR 2020"
                 link="https://aacrjournals.org/cancerres/article/80/16_Supplement/3417/642689/Abstract-3417-A-phase-II-basket-trial-of-dual-anti"
@@ -306,7 +481,10 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = {
                 Inclusion in Colon Cancer NCCN Guidelines V2.2024 and in Small
                 Bowel Adenocarcinoma NCCN Guidelines V3.2024
               </span>
-              <PMIDLink pmids="26028255, 31682550, 28734759, 37917058" />
+              <PMIDLink
+                pmids="26028255, 31682550, 28734759, 37917058"
+                wrapText
+              />
               <AbstractLink
                 abstract="Chae et al. Abstract# 3417, AACR 2020"
                 link="https://aacrjournals.org/cancerres/article/80/16_Supplement/3417/642689/Abstract-3417-A-phase-II-basket-trial-of-dual-anti"

diff --git a/src/main/webapp/app/pages/oncologyTherapiesPage/oncologyTherapiesPage.tsx b/src/main/webapp/app/pages/oncologyTherapiesPage/oncologyTherapiesPage.tsx
@@ -474,7 +474,7 @@ const OncologyTherapiesPage: React.FunctionComponent<{}> = props => {
                 'https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications'
               }
             >
-              Content current as of 4/23/2024
+              Content current as of 6/19/2024
             </Linkout>
           </div>
           <div>

diff --git a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json
@@ -2198,5 +2198,25 @@
     "targetedTx": "Y",
     "pxTx": "Y",
     "ngsTest": "Y"
+  },
+  {
+    "year": "2024",
+    "tx": "Tarlatamab",
+    "biomarker": "",
+    "agentClass": "Bispecific T-cell engager",
+    "drugTarget": "Bispecific DLL3-directed CD3 T-cell engager",
+    "targetedTx": "Y",
+    "pxTx": "N",
+    "ngsTest": "NA"
+  },
+  {
+    "year": "2024",
+    "tx": "Imetelstat",
+    "biomarker": "",
+    "agentClass": "Telomerase inhibitor",
+    "drugTarget": "Telomerase template antagonist",
+    "targetedTx": "Y",
+    "pxTx": "N",
+    "ngsTest": "NA"
   }
 ]
diff --git a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx
diff --git a/src/main/webapp/content/images/oncokb_summary.png b/src/main/webapp/content/images/oncokb_summary.png
diff --git a/src/main/webapp/index.html b/src/main/webapp/index.html
@@ -15,15 +15,15 @@
     <meta name="twitter:site" content="@oncokb">
     <meta name="twitter:title" content="OncoKB™ - MSK's Precision Oncology Knowledge Base">
     <meta name="twitter:description" content="OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.">
-    <meta name="twitter:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20240604">
+    <meta name="twitter:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20240702">
     <meta name="twitter:url" content="https://www.oncokb.org/">
 
     <meta property="og:site_name" content="OncoKB™">
     <meta property="og:type" content="website">
     <meta property="og:url" content="https://www.oncokb.org/">
     <meta property="og:title" content="OncoKB™ - MSK's Precision Oncology Knowledge Base">
     <meta property="og:description" content="OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.">
-    <meta property="og:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20240604">
+    <meta property="og:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20240702">
 
     <link rel="mask-icon" href="content/images/favicon/safari-pinned-tab.svg" color="#0968c3">
     <!-- Preload the customized fonts, so the html knows how to pain the page  -->